{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:57Z","timestamp":1761895977449},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Corcept for carrying out the SEISMIC study"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.mce.2014.09.021","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T22:21:40Z","timestamp":1414621300000},"page":"185-189","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Current approaches to the pharmacological management of Cushing's disease"],"prefix":"10.1016","volume":"408","author":[{"given":"Mark E.","family":"Molitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2014.09.021_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0020","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1210\/jc.2012-3200","article-title":"Approach to the Cushing's disease patient with persistent\/recurrent hypercortisolism after pituitary surgery","volume":"98","author":"Bertagna","year":"2013","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0030","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0035","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res. Clin. Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.mce.2014.09.021_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000314224","article-title":"Medical treatment of Cushing's syndrome; glucocorticoid receptor antagonists and mifepristone","volume":"92","author":"Castinetti","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.mce.2014.09.021_bib0045","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0050","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0055","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.mce.2014.09.021_bib0060","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0065","unstructured":"European Medicines Agency, 2013. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. EMA\/458028\/2013."},{"key":"10.1016\/j.mce.2014.09.021_bib0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1210\/jc.2012-3126","article-title":"Medical management of Cushing's disease","volume":"98","author":"Feelders","year":"2013","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0075","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.mce.2014.09.021_bib0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","article-title":"The burden of Cushing's disease: clinical and health-related quality of life aspects","volume":"167","author":"Feelders","year":"2012","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0085","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4158\/EP12149.RA","article-title":"A new therapeutic approach in the medical treatment of Cushing \u2018s syndrome: glucocorticoid receptor blockade with mifepristone","volume":"19","author":"Fleseriu","year":"2013","journal-title":"Endocr. Pract"},{"key":"10.1016\/j.mce.2014.09.021_bib0100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing's disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0110","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr. Rev"},{"key":"10.1016\/j.mce.2014.09.021_bib0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0003-4266(06)72611-7","article-title":"Use of cabergoline in persisting Cushing's disease","volume":"67","author":"Illouz","year":"2006","journal-title":"Ann. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0125","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0135","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJM197510302931802","article-title":"Cyproheptadine-induced remission of Cushing's disease","volume":"293","author":"Krieger","year":"1975","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.mce.2014.09.021_bib0140","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/jc.2012-2893","article-title":"Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients","volume":"98","author":"Lambert","year":"2013","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0145","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","article-title":"Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy","volume":"16","author":"Lila","year":"2010","journal-title":"Endocr. Pract"},{"key":"10.1016\/j.mce.2014.09.021_bib0150","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM197903013000903","article-title":"Treatment of Cushing's disease by o,p\u2019 DDD. Survey of 62 cases","volume":"300","author":"Luton","year":"1979","journal-title":"N. Engl. J. Med"},{"issue":"Pt 5","key":"10.1016\/j.mce.2014.09.021_bib0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann. Clin. Biochem"},{"key":"10.1016\/j.mce.2014.09.021_bib0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","article-title":"Late recurrences of Cushing's disease after initial successful transsphenoidal surgery","volume":"98","author":"Patil","year":"2008","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0170","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0746","article-title":"Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3171\/jns.1994.80.1.0037","article-title":"Early repeat surgery for persistent Cushing's disease","volume":"80","author":"Ram","year":"1994","journal-title":"J. Neurosurg"},{"key":"10.1016\/j.mce.2014.09.021_bib0190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","article-title":"Ketoconazole treatment in Cushing's syndrome; experience in 34 patients","volume":"35","author":"Sonino","year":"1991","journal-title":"Clin. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0195","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MED.0b013e32833ab069","article-title":"Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review","volume":"17","author":"Starke","year":"2010","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes"},{"key":"10.1016\/j.mce.2014.09.021_bib0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2265.1991.tb01737.x","article-title":"Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome","volume":"34","author":"Tabarin","year":"1991","journal-title":"Clin. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0210","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1210\/jc.2014-1054","article-title":"Next generation medical therapy for Cushing's syndrome \u2013 can we measure a benefit?","volume":"99","author":"Trainer","year":"2014","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.mce.2014.09.021_bib0215","unstructured":"United States Food and Drug Administration (U.S. FDA). 2013. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal livery injury and risk of drug interactions and adrenal gland problems. FDA Drug Safety Communications. 7\u201327-13, 1\u20136."},{"key":"10.1016\/j.mce.2014.09.021_bib0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane\u00a0has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"van Erp","year":"2011","journal-title":"Eur. J. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0225","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome","volume":"77","author":"Valassi","year":"2012","journal-title":"Clin. Endocrinol"},{"key":"10.1016\/j.mce.2014.09.021_bib0230","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.mce.2014.09.021_bib0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720714003013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720714003013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:50:38Z","timestamp":1538095838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720714003013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":40,"alternative-id":["S0303720714003013"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2014.09.021","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current approaches to the pharmacological management of Cushing's disease","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2014.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}